Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$15.7M
49M shares
52-week range
$0.27 – $2.38
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $16.4M | $19.9M | $1.9M | $0 |
| Cost of revenue | $463.0K | $777.0K | $0 | $2.5M | $1.8M | $1.8M | $1.6M |
| Gross profit | −$463.0K | −$777.0K | $0 | $13.9M | $18.2M | $71.0K | −$1.6M |
| Gross margin | — | — | — | 84.7% | 91.2% | 3.8% | — |
| R&D | $6.3M | $16.6M | $35.3M | $53.8M | $41.8M | $56.4M | $44.8M |
| Operating income | −$9.9M | −$22.4M | −$50.1M | −$56.1M | −$40.5M | −$73.6M | −$60.7M |
| EBITDA | −$9.4M | −$14.3M | −$49.8M | −$51.3M | −$32.5M | −$64.0M | −$53.9M |
| Net income | −$11.0M | −$14.9M | −$50.0M | −$53.8M | −$37.4M | −$70.5M | −$60.8M |
| Net margin | — | — | — | -328.1% | -187.4% | -3740.8% | — |
| EPS (diluted) | -0.38 | -0.98 | -10.94 | -1.86 | -1.05 | -1.63 | -1.33 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-0.89 | $-1.05–$-0.73 | 2 |
| 2027 | $3M | $-1.59 | $-1.59–$-1.59 | 1 |
| 2028 | $50000 | $-1.47 | $-1.47–$-1.47 | 1 |
| 2029 | $18M | $-0.98 | $-0.98–$-0.98 | 1 |
Forward consensus · source: Financial Modeling Prep
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
www.werewolftx.comNo one on the platform currently holds HOWL.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 516,218 | $429.8K |
No one on the platform has traded HOWL yet.
| $885690 |
| — |
| LITSLite Strategy, Inc. | $0.91 | +1.27% | $31M | — |
| NRXPNRx Pharmaceuticals, Inc. | $4.00 | +7.24% | $69M | — |
Source: Financial Modeling Prep · peers by sector/industry
@BiotechValues @longshot45 @LabPsycho $HOWL Well that’s what makes this an interesting play down here… you have a book value of 65-70c and some interesting upside if they can monetize some of these assets while avoiding anymore cash burn
View on StockTwits ↗@BiotechValues @LabPsycho @longshot45 $HOWL if you are looking for a “bottom”, watch the trade volume and especially big blocks to trade. If it happens it will be fast and brutal.
View on StockTwits ↗@LabPsycho @longshot45 $HOWL I think the handwringing about what RA might be seeing (which is a stretch anyways) misses the larger point. With ownership of 4.3mil shares, at 30c, RAs position is worth $1.3mil… which is almost exactly *1bp* of their AUM. The question is better put as why WOULDNT they sell, given that managing this position offers literally 0 upside to their investors, yet drains their own resources to hold and manage. This is simply a large holder cutting their loss and moving on. They will sell this as until it’s gone, fundamentals be damned
View on StockTwits ↗$HOWL @longshot45 Good detective work and post. I would expect, like BCAB did ~9 months ago, one last gasp / faux pump before / around the time of R/S. Good luck
View on StockTwits ↗@longshot45 $HOWL you must be joking- this could triple and it still wouldnt alter RAs quarterly returns by more than a bp. This position is meaningless to their portfolio
View on StockTwits ↗$HOWL I’m a little surprised we have not seen a lawsuit filed by RA Capital investors given the fact they waited until MPM sold their entire position and depressed the stock from about 1.5 down to the mid .30s before they started heavy duty selling themselves. Basically a wealth transfer from RA Capital shareholders to MPM. Still sucks for Howl owners but nothing we can do about that
View on StockTwits ↗$HOWL more heavy sales from RA ...guess howl staff will burn cash with their salaries after which they will pink sheet it. Classic move for bad managed bio business. Just my opinion.
View on StockTwits ↗$HOWL RA is still selling, so definitely not just trying to get to 9.9%. I have to question if they and MPM have access to info that is not public… Take a look at clinicaltrials NCT05479812 Study ends July 2026… so I fear these guy have access to see the current results before the study is even completed.
View on StockTwits ↗$HOWL Bought some yesterday. Will add more if goes down. 1/3 is done 2/3 rd next
View on StockTwits ↗$HOWL Good explanation on why RA is likely dropping to 9.9% exactly. You see this all the time in other tickers as well. It's not necessarily a bad thing. Gives them more flexibility to sell when news finally does drop.
View on StockTwits ↗$HOWL RA should be almost done selling. They got their main fund down to 9.9% exactly, no coincidence. The other fund has about 300k left.
View on StockTwits ↗$HOWL if I had to guess RA is trying to drop to under 10% ownership reporting requirements. If you look at 13d yesterday one of their funds is now exactly 9.9%..
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.